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Abstract
Objective To evaluate whether smoking status is associated with the
efficacy of antiplatelet treatment in the prevention of cardiovascular
events.
Design Systematic review, meta-analysis, and indirect comparisons.
Data sources Medline (1966 to present) and Embase (1974 to present),
with supplementary searches in databases of abstracts from major
cardiology conferences, the Cumulative Index to Nursing and Allied
Health (CINAHL) and the CAB Abstracts databases, and Google Scholar.
Study selection Randomized trials of clopidogrel, prasugrel, or ticagrelor
that examined clinical outcomes among subgroups of smokers and
nonsmokers.
Data extraction Two authors independently extracted all data, including
information on the patient populations included in the trials, treatment
types and doses, definitions of clinical outcomes and duration of
follow-up, definitions of smoking subgroups and number of patients in
each group, and effect estimates and 95% confidence intervals for each
smoking status subgroup.
Results Of nine eligible randomized trials, one investigated clopidogrel
compared with aspirin, four investigated clopidogrel plus aspirin
compared with aspirin alone, and one investigated double dose compared
with standard dose clopidogrel; these trials include 74 489 patients, of
whom 21 717 (29%) were smokers. Among smokers, patients
randomized to clopidogrel experienced a 25% reduction in the primary
composite clinical outcome of cardiovascular death, myocardial infarction,
and stroke compared with patients in the control groups (relative risk
0.75, 95% confidence interval 0.67 to 0.83). In nonsmokers, however,
clopidogrel produced just an 8% reduction in the composite outcome
(0.92, 0.87 to 0.98). Two studies investigated prasugrel plus aspirin
compared with clopidogrel plus aspirin, and one study investigated
ticagrelor plus aspirin compared with clopidogrel plus aspirin. In smokers,
the relative risk was 0.71 (0.61 to 0.82) for prasugrel compared with
clopidogrel and 0.83 (0.68 to 1.00) for ticagrelor compared with
clopidogrel. Corresponding relative risks were 0.92 (0.83 to 1.01) and
0.89 (0.79 to 1.00) among nonsmokers.
Conclusions In randomized clinical trials of antiplatelet drugs, the
reported clinical benefit of clopidogrel in reducing cardiovascular death,
myocardial infarction, and stroke was seen primarily in smokers, with
little benefit in nonsmokers.
Introduction
Antiplatelet drugs have become vital in the treatment of acute
coronary syndromes. Randomized clinical trials have
consistently found that clopidogrel, which has been available
for nearly two decades and is the most commonly used
adenosine diphosphate receptor blocker, reduces the incidence
offatalandnonfatalcardiovasculareventsinpatientswithacute
coronarysyndrome.Comparedwithtreatmentwithaspirinalone,
dual treatment with aspirin plus clopidogrel has been found to
reduce the rate of death and myocardial infarction and stroke
by 15% in patients with acute coronary syndrome.
1 Subgroup
analysesofrandomizedcontrolledtrials,however,haverecently
raised the question of whether such efficacy occurs primarily
or exclusively among smokers.
2
Clopidogrel is a prodrug that requires a two step metabolic
activation process to attain its active form. Cigarette smoking
induces the cytochrome P450 isoenzyme 1A2, a key enzyme
involved in the first activation step. Some authors have
hypothesized that smoking therefore increases the availability
of clopidogrel’s active metabolite, enhancing its efficacy.
Amongthenewerantiplateletagents,prasugrelisalsoaprodrug
but it undergoes a less complex activation process that is not
believedtoinvolveCYP1A2;ticagrelorisitselfanactivemoiety
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RESEARCHwhose metabolism only slightly involves CPY1A2. Therefore,
we hypothesized that the efficacy of clopidogrel, but not that
ofprasugrelandticagrelor,wouldbeenhancedamongsmokers.
We carried out a systematic review, meta-analysis, and series
of indirect comparisons to quantify the efficacy of clopidogrel
separately in smokers and nonsmokers and to compare the
efficacyofnewerantiplateletagentsinthesegroupsofpatients.
Methods
We followed the PRISMA guidelines for the conduct and
reporting of systematic reviews.
3
Search strategy and study selection
We systematically searched Medline and Embase databases up
to 18 July 2013 with no date or language restrictions. We
searched for all human randomized controlled trials evaluating
clopidogrel, prasugrel, or ticagrelor. Detailed search strategies
for each database are listed in the appendix. After excluding
duplicates, two authors (TJT and JGC) independently screened
the titles and abstracts of all identified articles to exclude those
that were not randomized trials, did not examine clinical
outcomes (such as only assessed platelet reactivity), or were
otherwise not relevant to our objectives. We obtained full text
versions of all remaining articles. We electronically searched
these articles for the word stems “smok*” and “tobacco” to
determine whether they were mentioned in the articles in any
places other than in the tables describing characteristics of
patients. We also searched for mention of the availability of
supplementary data using such terms as “appendi*”, “online”,
and “supplement”. We further reviewed the supplementary
materials for any mention of smoking or tobacco use. Two
authors (JJG and KB) evaluated each article that mentioned
smoking beyond the first table in either the main paper or
supplementaryappendixandincludedinthefinalanalysisthose
studies that reported clinical outcomes of antiplatelet treatment
in one or more smoking subgroups. Discrepancies at any stage
in the review process were resolved by group consensus.
In addition to the systematic search process, we searched for
studies in major cardiology conference abstract databases
(AmericanHeartAssociation,AmericanCollegeofCardiology,
European Society of Cardiology, and Heart Rhythm Society),
in the Cumulative Index to Nursing and Allied Health
(CINAHL)andtheCABAbstractsdatabases,andusingGoogle
Scholar. We also retrieved other meta-analyses of antiplatelet
agents and reviewed the studies included in those to identify
additional studies that might have been missed by the other
search strategies. Finally, we manually searched the reference
lists of relevant articles to locate additional studies.
Data extraction
From each study included in the analysis, we extracted
information about the antiplatelet treatment group, the control
treatment group, the definition of each clinical outcome, the
definitionofsmokingsubgroups,thenumberofpatientsineach
smokingcategory,andhazardratioand95%confidenceinterval
for each subgroup specific effect, or the information required
to calculate these. We used the Cochrane risk of bias tool to
assess whether studies were at low, high, or unclear risk of
selection bias, performance bias, detection bias, attrition bias,
or reporting bias.
4 Protocols and design and rationale papers
associated with each study were consulted as needed when
available. Two authors (JJG and KB) independently performed
alldataextractioninduplicateanddiscrepancieswerediscussed
until agreement was met.
Data analysis
Ourprimaryanalysiswasafixedeffectsmeta-analysisofhazard
ratios examining clopidogrel with or without aspirin compared
with aspirin alone or lower dose clopidogrel plus aspirin
(collectively referred to as “control arms”) separately among
smokers and nonsmokers. We focused on a composite clinical
outcomecomprisingcardiovasculardeath,myocardialinfarction,
andstroke,whichwastheprimaryoutcomeforallbutonestudy
included in the analysis, in which it was a secondary endpoint.
5
When studies reported results at multiple time points (for
example, at 28 days and at one year), we used the longer
follow-up time. When permitted by the data from the original
studies,weclassifiedcurrentsmokersassmokersandneverand
former smokers as nonsmokers. When studies reported results
for more than two smoking categories (for example, separate
estimates for former smokers, nonsmokers, and current
smokers), we used fixed effects meta-analyses to combine
groups as necessary (such as combining former and
nonsmokers). Presence of heterogeneity was assessed with the
Cochrane Q test and quantified with the I
2 test.
We conducted sensitivity analyses by omitting each study, one
at a time, from the primary analysis. For the CLARITY-TIMI
28 study, we also conducted a sensitivity analysis in which we
used that trial’s primary composite endpoint of thrombolysis in
myocardial infarction (TIMI) flow grade (TFG) 0 or 1 or death
orrecurrentmyocardialinfarctionbeforeangiographycouldbe
performed.
6 Finally, we assessed the potential for publication
bias by visually inspecting the funnel plot.
7
Two studies examined prasugrel plus aspirin compared with
clopidogrelplusaspirin;wecombinedthemusingafixedeffects
meta-analysisseparatelyforsmokersandnonsmokers.Wethen
used indirect analyses to compare prasugrel and ticagrelor with
the control arms from the original clopidogrel trials and to
compare prasugrel with ticagrelor. We used Bucher’s method
to make each of the three pairwise indirect comparisons
separately.
8
Results
Literature search
We identified 1190 unique articles from the Medline and
Embase searches, of which we excluded 1021 based on the title
and abstract screening. From the remaining 169 articles, we
further excluded 153 that did not mention smoking or tobacco
except as a baseline characteristic and nine articles that
mentioned smoking but did not present smoking related
subgroup findings. The other search strategies yielded two
additional studies, resulting in a total of nine studies that we
included in analyses (fig 1)⇓.
6 9-23
Sixstudiesevaluatedclopidogrelastheinterventionofinterest:
one examined clopidogrel alone compared with aspirin,
9 14 four
examined clopidogrel plus aspirin compared with placebo plus
aspirin,
6 11 13 16 18-20 23 and one examined double dose compared
withstandarddoseclopidogrelwithhigherorlowerdoseaspirin
inafactorialdesign
16(table1⇓).Twostudiesexaminedprasugrel
compared with clopidogrel
15 17 22 and one study examined
ticagrelor compared with clopidogrel,
12 21 all among patients
also treated with aspirin (table 1). All original trials were of
highqualityasnoneexhibitedhighriskofbiasonanyCochrane
risk of bias tool domain (appendix).
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Among the six studies that examined clopidogrel compared
with control arms, all were conducted in patients with
establishedcardiovasculardisease.(TheCHARISMAtrialalso
included patients at high risk for cardiovascular events as
definedbythepresenceofmultipleriskfactors,butonlypatients
with established cardiovascular diseases were included in the
smokingsubgroupanalysis.
10 11)Onewasconductedspecifically
in patients scheduled to undergo percutaneous coronary
intervention.
19 20 Across trials, follow-up ranged from up to 30
days to up to three years. A total of 74 489 patients, of whom
21717(29%)weresmokers,wereincludedinthemeta-analysis
of clopidogrel versus control arms.
In smokers, clopidogrel reduced the risk of the composite
clinical endpoint by 25% (relative risk 0.75, 95% confidence
interval 0.67 to 0.83; fig 2⇓). However, there was only an 8%
reductionamongnonsmokers(0.92,0.87to0.98).Nostatistical
heterogeneity was observed across studies in either smoking
stratum(Q=8.0,P=0.16,I
2=0.01amongsmokers;Q=5.3,P=0.38,
I
2=0.00 among nonsmokers).
We observed similar results in the sensitivity analysis in which
we used the primary composite endpoint of thrombolysis in
myocardial infarction (TIMI) flow grade (TFG) 0 or 1 or death
orrecurrentmyocardialinfarctionbeforeangiographycouldbe
performedfromtheCLARITY-TIMI28study.Thefixedeffects
relative risk was 0.73 (95% confidence interval 0.66 to 0.80) in
smokersand0.91(0.86to0.96)innonsmokers.Inthisanalysis,
we did observe some heterogeneity in the smoker stratum
(Q=12.1, P=0.03, I
2=0.03) but not in the nonsmoker stratum
(Q=10.3, P=0.07, I
2=0.01). Results were consistent across
sensitivity analyses in which we separately omitted a single
study from the primary analysis (table 2⇓). The small number
of studies limits inference from the funnel plots (appendix), but
no publication bias was apparent.
Indirect comparison of antiplatelet agents
Among smokers, prasugrel was associated with a further
reductioninthecompositeendpointcomparedwithclopidogrel
(relative risk 0.71, 95% confidence interval 0.61 to 0.82; fig
3⇓). The corresponding estimate comparing ticagrelor and
clopidogrel was lower, at 0.83 (0.68 to 1.00). Both newer
antiplatelet agents led to a lower incidence of the endpoint
compared with the control arms of the clopidogrel trials
(prasugrel 0.53, 0.44 to 0.64; ticagrelor 0.62, 0.50 to 0.78). The
relative risk for prasugrel compared with ticagrelor in smokers
was 0.85 (0.67 to 1.09).
Innonsmokers,weobservedmodestreductionsinthecomposite
endpoint for prasugrel compared with clopidogrel (relative risk
0.92, 95% confidence interval 0.83 to 1.01) and for ticagrelor
compared with clopidogrel (0.89, 0.79 to 1.00; fig 3⇓). In
indirect comparisons, nonsmokers given prasugrel (0.85, 0.76
to 0.95) and ticagrelor (0.82, 0.72 to 0.93) had lower incidence
of the composite endpoint compared with the group of controls
used in the clopidogrel trials. We found no difference between
prasugrel versus ticagrelor (1.03, 0.88 to 1.20) among
nonsmokers.
Discussion
This meta-analysis showed that in smokers, clopidogrel was
associated with a 25% reduction in a composite outcome
comprising cardiovascular death, myocardial infarction, and
stroke,buttherewasonlyan8%reductionamongnonsmokers.
Onlytwostudieslookedatprasugrelcomparedwithclopidogrel
andonelookedatticagrelorcomparedwithclopidogrel;inthese
trials,thenewerantiplateletdrugsseemedtobemoreefficacious
than clopidogrel among smokers and marginally more
efficacious than clopidogrel among nonsmokers. To our
knowledge this is the first meta-analysis of data from
randomizedtrialstoassesstheeffectofsmokingontheefficacy
ofantiplateletdrugs.Unlikethepreviouslydescribed“smoker’s
paradox,”
24inwhichsmokerswerecomparedwithnonsmokers,
we evaluated the effect of antiplatelet treatment on
cardiovascular outcomes in smokers and nonsmokers.
Potential mechanisms
Clopidogrel is a prodrug that undergoes a two step activation
processmediatedpredominantlybythecytochromeP450hepatic
enzymesystem.
25Polycyclicaromatichydrocarbonsincigarette
smoke are known to induce CYP1A2, an enzyme involved in
the first activation step. Thus, smoking can enhance the
availability of the active metabolite and reduce the proportion
of prodrug eliminated without activation.
26 A recent
pharmacokineticandpharmacodynamicstudyobservedgreater
platelet inhibition by clopidogrel in smokers than in
nonsmokers.
27
While CYP1A2 induction offers one plausible explanation for
enhancedclopidogrelactivity,prasugrel,whichisalsoaprodrug,
undergoesalesscomplexactivationprocessthatisnotbelieved
to involve CYP1A2.
28 We therefore hypothesized that smoking
statuswouldmodifyprasugrel’sefficacytoamuchlesserextent.
Ouranalysis,however,foundthatthebenefitsofprasugreland,
to a lesser extent, ticagrelor, which is an active compound
metabolized predominantly by CYP3A4, also seem enhanced
among smokers. The previously mentioned pharmacokinetic
and pharmacodynamic study also found greater platelet
inhibition by prasugrel in smokers than in nonsmokers, but the
results did not reach significance.
27
In addition to metabolizing ticagrelor, CYP3A4 is also the
primaryhepaticenzymeinvolvedintheconversionofprasugrel
to its active metabolite and is also the main enzyme involved
in the second step of clopidogrel’s activation.
28 While
up-regulation of CYP3A4 would theoretically affect the
metabolism of all three agents (but in different ways), and
smoking has recently been observed to increase the induction
of 3A4 in the presence of a known inducer, there is no strong
evidence to suggest that smoking itself induces this enzyme.
29
Alternatively, a pharmacodynamic mechanism could be
responsible for the observed effects.
Althoughtheexactmechanismbywhichsmokingmightenhance
the activity of antiplatelet agents is not known, five out of the
sixstudiesinouranalysisthatcomparedclopidogrelwithcontrol
arms found a larger benefit of clopidogrel in smokers than
nonsmokers. We did not observe any statistical heterogeneity
among results in each subgroup, despite minor differences in
definitions of baseline smoking status, differences in patient
populations, differences in control treatments, and differences
in durations of follow-up. Our results were robust across
sensitivity analyses, and we found no strong evidence for
potential publication bias, though the number of studies was
small, limiting such inference. Taken together, these results
suggest that, at doses evaluated in phase III trials and currently
used in practice, clopidogrel is associated with a substantial
reduction in the composite outcome of cardiovascular death,
myocardial infarction, and stroke among patients who smoke
and only a modest benefit in patients who do not smoke. If
confirmed, these findings might support different approaches
to the use of these drugs in smokers and nonsmokers.
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greater than expected based on overall trial results, it is critical
to understand whether these patients are also at an increased
risk of major bleeds, which could alter risk-benefit
considerations.Ofthestudiesidentifiedinoursystematicsearch,
only the CHARISMA trial presented data on bleeding events
in those randomized to clopidogrel compared with controls in
smoking subgroups. The hazard ratios for severe or moderate
bleeding for clopidogrel plus aspirin compared with aspirin
alone were 1.31 (95% confidence interval 0.90 to 1.90) among
never smokers, 1.43 (1.05 to 1.95) among former smokers, and
1.62 (1.02 to 2.58) among current smokers, suggesting a
potential gradient of increased risk of bleeding across smoking
status.
10 The authors who investigated the effect of clopidogrel
withinsmokingstrataintheCLARITY-TIMI28trialnotedthat
there was “no statistically significant interaction between
smoking and clopidogrel on the risk of TIMI major or minor
bleeding,”
13buttheanalysismighthavebeenunderpoweredfor
such an interaction test. In the TRILOGY trial, the hazard ratio
formajorbleedingrelatedtonon-coronaryarterybypassgrafting
forprasugrelcomparedwithclopidogrelwas1.72(0.68to4.37)
in current or recent smokers and 1.18 (0.68 to 2.05) in not
currentorrecentsmokers.
17InthePLATOtrial,thehazardratio
for major bleeding with ticagrelor compared with clopidogrel
was 1.18 (0.98 to 1.43) in current smokers and 1.04 (0.92 to
1.18) in former and nonsmokers.
12
Our finding that clopidogrel confers little benefit among
nonsmokers has particularly important implications in light of
the decreasing prevalence of smoking in developed countries.
Clinicians should carefully consider the potential benefits and
risks of antiplatelet drugs differently for smokers and
nonsmokers. In particular, these findings suggest that
nonsmokersarelikelytoderivelessbenefitfromtreatmentwith
antiplatelets. On the other hand, while smokers might be more
likelytobenefitfromtreatment,theenhancedantiplateleteffect
might also increase the risk of bleeding, though this needs to
be confirmed in future studies. Future studies should also
investigate whether different doses should be used in smokers
and nonsmokers.
We examined the possibility that our findings could be because
smoking status is a marker for higher risk of cardiovascular
outcomes.Whendatawereavailableforeachoftheclopidogrel
trials, we compared outcome frequencies among smokers and
nonsmokers in the control groups. The cumulative incidence of
the primary outcome was not systematically higher in smokers.
Smokers had a higher incidence in the CREDO trial (13.8% v
10.7% in nonsmokers)
19 but a lower incidence in
CURRENT-OASIS 7 (3.6% v 4.8% in nonsmokers)
16 and the
CURE trial (9.4% v 10.9% in never smokers and 13.1% in
former smokers).
18 Incidences were similar for smokers and
nonsmokers in the CAPRIE trial (10.8% v 10.6%)
14 and in
CLARITY-TIMI 28 (13.9% v 14.1%).
13 Furthermore, smokers
tended to be younger and healthier than nonsmokers, and we
did not find evidence of a greater effect of clopidogrel in other
high risk subgroups. For example, the CURE investigators
classified patients into low, intermediate, and high risk
subgroups for the primary cardiovascular outcome and found
that, compared with placebo, those in the high risk subgroup
were least likely to benefit from clopidogrel.
23
Limitations
The limitations of this study must be considered when
interpretingitsresults.First,wereliedonstudiesinthepublished
literature,whichcouldleadtodistortionsfrompublicationbias.
While our assessment for publication bias did not show major
concerns, it was limited by the small number of studies. We do
not expect much publication bias related to the primary results
oflargerandomizedtrials,butwecannotruleoutthepossibility
that ad hoc subgroup analyses of these trials have been
conducted but not reported. Moreover, the subgroup analyses
of smoking status were prespecified in some, but not all, of the
originalrandomizedtrials. In addition,someof the data thatwe
included were culled from conference abstracts that have not
undergone rigorous peer review. Further, patient populations,
study entry criteria, comparator treatments, trial durations, and
classificationsofsmokingstatusdifferedamongstudies.Despite
these differences, the results for clopidogrel compared with
controls in smokers versus nonsmokers were consistent across
studies and in sensitivity analyses. Our analyses require the
assumption that randomization of treatment was successful
within smoking subgroups, which is likely in such large trials.
Finally, the indirect comparison methods require that the
included trials be similar with respect to potential modifiers of
treatmenteffectwithinsmokingsubgroups.Thelackofobserved
heterogeneity suggests that this is true, at least for the
clopidogrel trials. With respect to trials comparing prasugrel
with clopidogrel, the application of this approach is limited by
thefactthattheTRITON-TIMItrialincludedpatientsscheduled
toundergopercutaneousintervention,
22whereastheTRILOGY
trial included patients not scheduled to undergo
revascularization.
17 The results stratified by smoking status,
however, were qualitatively similar in these two trials.
Conclusion
On the whole, the available analyses of randomized trial
subgroupssuggestthattheefficacyofantiplateletsdiffersamong
smokers and nonsmokers, with the benefit of these drugs
occurringprimarilyamongsmokersandfarlessevidenceofthe
drugs’ efficacy in nonsmokers. Little is known about how
smokingaffectsbleedingassociatedwithantiplatelettreatment.
Post hoc analyses of existing antiplatelet trials that collected
baseline smoking information can both augment our efficacy
findings and shed light on potential differences in bleeding risk
associated with smoking status in patients treated with
antiplatelets. Different risk-benefit considerations might be
required for smokers and nonsmokers.
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RESEARCHTables
Table 1| Characteristics of studies included in meta-analysis and indirect comparisons of effect of antiplatelet drugs
Relative risk
(95% CI)
No of
patients
Smoking
subgroup
Overall
incidence
Follow-up
duration
Outcome
definition Treatment2 Treatment1 Patient population Study
Clopidogrel v control (aspirin, placebo, or low dose clopidogrel)
0.98
(0.88 to 1.09)*
13 516 Never and former
smokers
10.2% Up to 3
years of
follow-up;
mean
follow-up,
1.9 years;
Composite of
death from
cardiovascular
causes,
nonfatal
myocardial
Aspirin 325
mg daily
Clopidogrel
75 mg daily
Patients with
atherosclerotic
disease manifested
as either recent
ischemic stroke,
recent myocardial
CAPRIE
9,14
0.76
(0.64 to 0.90)*
5688 Current smokers
mean
treatment
duration, 1.6
years
infarction,
nonfatal stroke
infarction, or
symptomatic
peripheral artery
disease
0.85
(0.76 to 0.96)†
9666 Never and former
smokers
10.3% Up to 12
months;
mean
duration of
treatment, 9
months
Composite of
death from
cardiovascular
causes,
nonfatal
myocardial
Placebo Clopidogrel
75 mg daily
Patients with acute
coronary
syndromes who did
not have ST
segment elevation
and treated with
aspirin
CURE
18,23
0.63
(0.48 to 0.83)
2893 Current smokers
infarction,
nonfatal stroke
0.90
(0.63 to 1.29)‡
1433 Nonsmokers 10.1% Up to 12
months
Composite of
1 year death,
myocardial
infarction,
stroke
Placebo
before PCI
followed by
clopidogrel
75 mg daily
throughday
Clopidogrel
300 mg
loading
dosebefore
PCI
followed by
75 mg daily
Patients who were
to undergo elective
PCI or were
deemed at high
likelihood of
undergoing PCI and
treated with aspirin
CREDO
19,20
0.44
(0.23 to 0.83)
647 Smokers
28 followed
by placebo
0.91
(0.68 to 1.20)
1732 Nonsmokers 12.7% Up to 30
days of
follow-up
30 day
composite of
death from
cardiovascular
causes,
recurrent
Placebo Clopidogrel
75 mg daily
Patients with ST
segment elevation
myocardial
infarction treated
with aspirin, a
fibrinolytic, and
heparin
CLARITY-TIMI
28
6,13
0.64
(0.47 to 0.89)¶
1697 Smokers
nonfatal
myocardial
infarction,
recurrent
nonfatal
ischemia§
0.86
(0.74 to
1.00)††
9733 Never and former
(patients who
smoked ≥1
cigarette/day any
time before month
before enrollment)
smokers
7.4% Up to 42
months of
follow-up;
median
follow-up,
28 months
Composite of
death from
cardiovascular
causes,
nonfatal
myocardial
infarction,
Placebo Clopidogrel
75mg daily
Patients with
evidence of
cardiovascular
disease treated with
aspirin**
CHARISMA
10,11
nonfatal
stroke-
0.93
(0.71 to 1.22)
2419 Current smokers
(patients who
smoked ≥1
cigarette/day during
month before
enrollment)
0.99
(0.87 to
1.15)‡‡
16 701 Not current tobacco
users
4.3% Up to 30
days of
follow-up
30 day
composite of
death from
cardiovascular
causes,
nonfatal
Clopidogrel
300 mg
loading
dose
followed by
75 mg
thereafter
Clopidogrel
600 mg
loading
dose
followed by
150 mg
daily for 6
Patients with acute
coronary syndrome
referred for an
invasive strategy
and treated with
either higher dose
(300-325 mg daily)
CURRENT-OASIS
7
16
0.80
(0.64 to
1.02)‡‡
8373 Current tobacco
users
myocardial
infarction,
nonfatal stroke
days and
75 mg
thereafter
or lower dose (75
100 mg daily)
aspirin
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RESEARCHTable 1 (continued)
Relative risk
(95% CI)
No of
patients
Smoking
subgroup
Overall
incidence
Follow-up
duration
Outcome
definition Treatment2 Treatment1 Patient population Study
Prasugrel v clopidogrel
0.84
(0.74 to 0.96)
8437§§ Nonsmokers 11.0% Up to 15
months of
follow-up;
median
duration of
treatment,
14.5 months
Composite of
death from
cardiovascular
causes,
nonfatal
myocardial
infarction,
nonfatal stroke
Clopidogrel
75 mg daily
Prasugrel
10 mg daily
Patients with
moderate to high
risk acute coronary
syndromes with
scheduled PCI and
treated with aspirin
TRITON-TIMI
38
15,22
0.76
(0.64 to 0.91)
5171§§ Smokers
1.06
(0.90 to 1.24)
5614 Not current or
recent smoker
14.9% Up to 30
months of
treatment;
median
follow-up,
17.1
Composite of
death from
cardiovascular
causes,
nonfatal
myocardial
Clopidogrel
75 mg daily
Prasugrel
10 mg daily
Patients aged <75
with acute coronary
syndromes treated
with aspirin and not
scheduled to
undergo
revascularization¶¶
TRILOGY
17
0.54
(0.39 to 0.74)
1566 Current or recent
smoker (patients
who smoked
cigarettes within 30
days before
randomization)
months;
median
duration of
infarction,
nonfatal stroke
treatment,
14.8 months
Ticagrelor v clopidogrel
0.89
(0.79 to 1.00)
9311*** Nonsmokers
(patients who
reported no current
or previous
smoking) and
ex-smokers
10.8% Up to 12
months of
follow-up;
median
duration of
treatment,
9.1 months
Composite of
death from
cardiovascular
causes,
nonfatal
myocardial
infarction,
nonfatal stroke
Clopidogrel
75 mg daily
Ticagrelor
90 mg
twice daily
Patients with acute
coronary
syndromes treated
with aspirin
PLATO
12,21
(patients who
previously smoked
but stopped more
than month before
randomization)
0.83
(0.68 to 1.00)
5196*** Habitual smokers
(patients who
reported smoking
≥1 cigarette, cigar,
or equivalent
tobacco/day)
PCI=percutaneous coronary intervention.
*Hazard ratios and 95% confidence intervals from Gurbel et al.
2
†Combined estimates for never and former smokers with fixed effects meta-analysis.
‡Cumulative incidence ratio and 95% confidence intervals calculated from abstract presented at Innovation in Intervention: i2 Summit 2006.
19
§Primary endpoint in CLARITY-TIMI 28 study was composite of thrombolysis in myocardial infarction (TIMI) flow grade (TFG) 0 or 1 or death or recurrent myocardial
infarction before angiography could be performed. We selected 30 day clinical endpoint, which is more consistent with primary endpoints of other trials.
¶Combined estimates from 1–9, 10–19, 20–29, and ≥30 cigarettes/day subgroups with fixed effects meta-analysis.
**CHARISMA trial included patients with established cardiovascular disease as well as those at high risk for cardiovascular events as defined by presence of
multiple risk factors, but patients without established cardiovascular disease were excluded from post hoc smoking analysis because smoking was entry criterion
for such patients.
††Combined estimates for never and former smokers with fixed effects meta-analysis.
‡‡Calculated 95% confidence intervals from data in figure 3 of CURRENT-OASIS 7 publication.
16
§§Estimated from TRITON-TIMI 38 original publication (38% of 13 608 patients had tobacco use at baseline).
22
¶¶TRILOGY trial included secondary population comprising patients aged ≥75 in whom prasugrel 5 mg was compared with clopidogrel 75 mg. Results stratified
by smoking status were available only for primary cohort of patients aged <75 in whom prasugrel 10 mg was compared with clopidogrel 75 mg.
*** PLATO trial enrolled 18 624 patients, but only 14 507 were included in analysis stratified by smoking status.
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RESEARCHTable 2| Sensitivity analyses omitting each study one at a time from primary analysis of clopidogrel compared with controls and efficacy
of antiplatelet drugs in prevention of cardiovascular events
Relative risk (95% CI)
Study omitted Nonsmokers Smokers
0.92 (0.87 to 0.98) 0.75 (0.67 to 0.83) None (primary analysis)
0.90 (0.84 to 0.96) 0.74 (0.65 to 0.84) CAPRIE
0.95 (0.87 to 1.02) 0.77 (0.69 to 0.86) CURE
0.92 (0.87 to 0.98) 0.76 (0.68 to 0.84) CREDO
0.92 (0.87 to 0.98) 0.76 (0.68 to 0.85) CLARITY-TIMI 28
0.93 (0.88 to 0.99) 0.72 (0.64 to 0.80) CHARISMA
0.90 (0.85 to0.97) 0.73 (0.65 to 0.82) CURRENT-OASIS 7
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RESEARCHFigures
Fig 1 Flow of identification and inclusion of studies of antiplatet drugs
Fig 2 Efficacy of clopidogrel stratified by baseline smoking status. *Cumulative incidences in each treatment arm were not
reported within smoking subgroups in CHARISMA trial. †Cumulative incidences presented here for CURE trial are only for
never smokers. Cumulative incidences for former smokers were 10.3% in clopidogrel arm and 13.1% in control arm
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RESEARCHFig 3 Hazard ratios for clopidogrel, prasugrel, ticagrelor, and controls in mixed treatment comparisons. Solid lines indicate
estimates based on direct comparisons between two treatments. Dashed lines indicate estimates derived from indirect
comparisons
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